Health Robotics has revealed its great success at the 2011 Annual Symposium of the European Association of Hospital Pharmacists (EAHP) in Vienna, with respect to its robots CytoCare and i.v.STATION.
Gaspar DeViedma, the Executive Vice President of Health Robotics was given an invitation to share the financial, clinical and throughput/efficiency outcomes obtained from the global installation of its robots at 45 locations. DeViedma’s first task was to thank the hospital participants in the program named i.v.STATION Beta-Test. This program concluded by January 2011. Later, he spoke about the results obtained from the installations after the finish of the Beta-Tests. He specified that the outcomes included an average ROI of six months, an average throughput of 35 patient specific IV dosages per hour, with no drug exchange errors and no labeling errors, with no details of cross-contamination and drug quantity, which are ISO7886-1 compliant and the 100% success achieved in sterility.
According to De Viedma, the hosting visits in the i.v.STATION hospitals have a gone a long way to prove the benefits, flexibility and the features included in the production environment. The i.v.SOFT Assist and the i.v.STATION, which are being used productively, could be verified by industry experts and prospective customers, especially with regard to its much admired vision to develop beyond Oncology Automation. He further mentioned that an added benefit was gained from the successful outcomes, which was the capacity to re-use the majority of the completely tested i.v.STATION tools along with the company’s new robot i.v.STATION ONCO, much before their competitors were able to justify their claims of handling chemotherapy automation for the past twenty years or more.
After the keynote address, DeViedma introduced the new robot for cancer therapy the i.v.STATION ONCO. He also disclosed the throughput/efficiency and clinical outcomes, which were experienced by hospitals at the Asia-Pacific, European and American hospitals while using the CytoCare, which was the first ever robot for cancer therapy. To conclude, DeViedma commented that the company was highly appreciative of the i.v.STATION Betas in America, where there were several delays in installations mainly because of the ex-distributors of Health Robotics’ refusal to take part in the Beta-Test installations, which led to the hiring of the local engineering staff. The company was eagerly waiting to repeat the Beta Tests with the new i.v.STATION ONCO and the TPNstation robots during 2011 and 2012 respectively. This time the control of the tests would not be handed over to the distribution partners of Health Robotics, which would eliminate delays and help in completing the tests on time.
Source: http://www.health-robotics.com